Concomitant use of anti-dementia drugs with psychotropic drugs in Norway-a population-based study

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 12, 2011, Pages 1319-1326

  Langballe, Ellen Melbye ^a   Engdahl, Bo ^a   Selbæk, Geir ^b,c   Nordeng, Hedvig ^a,d  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b INNLANDET HOSPITAL TRUST   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Anti dementia drugs; Concomitant use; Prescription database; Psychotropic drugs

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CLOZAPINE; DONEPEZIL; DOXEPIN; HALOPERIDOL; LEVOMEPROMAZINE; MEMANTINE; NOOTROPIC AGENT; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; PROCHLORPERAZINE; PSYCHOTROPIC AGENT; RIVASTIGMINE;

AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PHARMACY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM AGENTS; DATABASES, FACTUAL; DEMENTIA; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; NORWAY; PSYCHOTROPIC DRUGS; SEX FACTORS;

EID: 81955162983     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2211     Document Type: Article

References (36)

1. Harvey RA, Champe PC, Mycek MJ. Pharmacology. Lippincott Williams & Wilkins: Philadelphia, 2006.
2. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006; 6(1): 61-67.
3. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. Functional outcomes of drug treatment in Alzheimer's disease - A systematic review and meta-analysis. Drugs Aging 2007; 24(2): 155-167.
4. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6(9): 782-792.
5. Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psych 2010; 25: 547-553.
6. Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002; 52(3): 243-252.
7. Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. J Neurol Sci 2005; 236(1-2): 43-48.
8. Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes - A 12-month follow-up study. Am J Geriatr Psychiatry 2008; 16(7): 528-536.
9. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2007; 23(2): 170-177.
10. Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribingin people with dementia: a populationdatabase study. Age Ageing 2010; 39: 637-642.
11. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: A clinical review. Clin Interv Aging 2009; 4: 225-233.
12. Seritan AL. How to prevent drug-drug interactions with cholinesterase inhibitors. Curr Psychiatry 2008; 7(2): 57-67.
13. Giron MST, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J. Psychotropic drug use in elderly people with and without dementia. Int J of Ger Psychiatry 2001; 16(9): 900-906.
14. Johnell K, Fastbom J. Concurrent Use of Anticholinergic Drugs and Cholinesterase Inhibitors: Register-Based Study of Over 700 000 Elderly Patients. Drugs Aging 2008; 25(10): 871-877.
15. Trifirò G, Sini G, Sturkenboom MCJM, et al. Prescribing pattern of antipsychotic drugs in the Italian general population 2000-2005: a focus on elderly with dementia. Int Clin Psychopharmacol 2010; 25(1): 22.
16. Norwegian prescription database (NorPD). Oslo: Norwegian Institute of Public Health.
17. Rønning M, Berg Ch, Litleskare I, Mahic M, Sakshaug S, Selmer R, et al. The Norwegian Prescription Database 2004-2008 (Rep.No.2009:1). In Legemiddelstatistikk 2009:2 Reseptregisteret. Norwegian Institute of Publich Health: Oslo, 2009. ISBN: 978-82-8082-198-0
18. The Norwegian Labour and Welfare Administration. Kontrollordningen for blå resept. Kontroll av legers forskrivning på refusjonspunkt 7i. Demens. Lokal kontroll nr 1/2005. [Control of physicians percription of dementia drugs according to reimbursement regulation 7i.] (accessed 1 May 2010).
19. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2008. 11. 2007. Oslo.
20. Spigseth O (ed.) (2010) Norwegian drug information database. (accessed 1 May 2010).
21. Medbase: SFINX (Swedish, Finnish, INteraction X-referencing). Medbase Ltd in Turku, Finland, the Karolinska Institute Department of Clinical Pharmacology in Stockholm, Sweden, and the Division of Drug Management and Informatics at Stockholm County Council, Sweden, 2010.
22. Kroger E, van Marum R, Souverein P, Egberts T. Discontinuation of Cholinesterase Inhibitor Treatment and Determinants thereof in the Netherlands: A Retrospective Cohort Study. Drugs Aging 2010; 27: 663-675.
23. Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioral disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psych 2007; 22(9): 843-849.
24. Lyketsos CG, Steele C, Baker L, et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997; 9(4): 556-561.
25. Starkstein SE, Mizrahi R, Power BD. Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int Rev Psychiatr 2008; 20(4): 382-388.
26. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia A review of the evidence. JAMA 2005; 293: 596-608.
27. Curran S, Turner D, Musa S, Byrne A, Wattis J. Use of hypnotics in older people with mental illness: a systematic study of tolerability and use in different diagnostic groups. LDRP 2007; 4(1): 55-64.
28. Scott MA, Stigleman S, Cravens D. What is the best hypnotic for use in the elderly? J Family Practice 2003; 52(12): 976-978.
29. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf 2004; 3(5): 485-493.
30. SBU - The Swedish Council on Thecnology Assessment in Health Care. Dementia - Diagnostic and Therapeutic Interventions. A systematic Rewiev. (Rep. No. 2). Stockholm, Sweden, 2008. ISBN: 978-91-85413-24-9
31. Schor JD, Levkoff SE, Lipsitz LA, et al. Risk factors for delirium in hospitalized elderly. JAMA 1992; 267(6): 827-831.
32. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59(1): 1-12.
33. Barton C, Sklenicka J, Sayegh P, Yaffe K. Contraindicated medication use among patients in a memory disorders clinic. Am J Ger Pharmacother 2008; 6(3): 147-152.
34. Midlöv P, Eriksson T, Kragh A. Drug-related Problems in the Elderly. Dordrecht: Springer, Netherlands, 2009.
35. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370: 173-184.
36. Ruths, S. Evaluation of prescribing quality in nursing homes based on drug-specific indicators: The Bergen district nursing home (BEDNURS) study. Norsk Epidemiologi 2009; 18(2): 173-178.